Recently, angiogenesis was identified an effective and important target of pharmacological strategies against BC; for example, using monoclonal antibodies against VEGF and the VEGF receptor.42 There is an urgent need to discover new and improved anti-angiogenic agents to treat for patients with BC. This evidence concerns the gene VEGFA and breast cancer.